Effects of Subinhibitory Concentrations of Moxifloxacin in an<i>In-Vitro</i>Dynamic Model

Maggiolo, Franco; Capra, Ruggero; Bartoli, A.; Bottura, P.; Migliorino, M.; Suter, Fredy

doi:10.1179/joc.2000.12.2.129

Cited by 6 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study we administered moxifloxacin associated with amoxicillin or tinidazole with an excellent eradication rate. Our observations show that moxifloxacin may be a promising alternative to anti‐ H. pylori schemes 27–29 . Moxifloxain based schemes may improve patient's compliance for the low occurrence of side effects, and for the administration of only one pill daily.…”

Section: Discussionmentioning

confidence: 77%

“…Our observations show that moxifloxacin may be a promising alternative to anti-H. pylori schemes. [27][28][29] Moxifloxain based schemes may improve patient's compliance for the low occurrence of side effects, and for the administration of only one pill daily. In particular, a lower incidence of diarrhoea and taste disturbance was observed in moxifloxacin groups than in clarithromycin groups.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Moxifloxacin‐based strategies for first‐line treatment of Helicobacter pylori infection

Nista¹,

Candelli²,

Zocco³

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Standard anti-Helicobacter pylori therapy may not achieve a satisfactory eradication rate. Fluoroquinolones, such as moxifloxacin, are safe and promising agents for H. pylori eradication. Aim: To compare the efficacy of two 1-week moxifloxacin-based H. pylori eradication regimens with two standard treatments. Methods: Three hundred and twenty H. pylori-positive subjects were randomized into four groups to receive: moxifloxacin, amoxicillin, esomeprazole (Group MAE); moxifloxacin, tinidazole and esomeprazole (Group MTE); standard triple therapies with clarithromycin, amoxicillin and esomeprazole (Group CAE) or tinidazole (Group CTE) for 7 days. H. pylori status was re-assessed 6 weeks after the end of therapy by 13C urea breath test.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Moxifloxacin‐based strategies for first‐line treatment of Helicobacter pylori infection

Nista¹,

Candelli²,

Zocco³

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…These preliminary observations indicate that moxifloxacin may be a promising alternative in anti‐ H. pylori schemes 44–46 . Moxifloxacin‐based schemes may allow improved patient compliance with a lower occurrence of side‐effects, and the administration of only one pill daily in mono therapy and two or four pills daily in dual or triple regimens, respectively.…”

Section: Discussionmentioning

confidence: 92%

Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication

Ojetti

Zocco

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H. pylori‐positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention‐to‐treat and per protocol analyses were performed. Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Conclusions: Mono and dual moxifloxacin‐based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin‐based triple therapy may be considered as a new, effective, first‐line therapy option.

show abstract

“…Inoltre, manifesta un significativo effetto post-antibiotico (PAE) sia nei batteri Gram-positivi sia nei batteri Gram-negativi. L'effetto postantibiotico varia come durata nei vari patogeni da circa 1,5 a 2,5 ore [62,63].…”

Section: Farmacodinamicaunclassified

Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomico

Eandi

2003

View full text Add to dashboard Cite

PREMESSEMoxifloxacina è un nuovo fluorochinolone di recente introduzione nell'armamentario terapeutico per il trattamento antibiotico delle infezioni delle basse ed alte vie respiratorie [1][2][3][4][5][6][7].Moxifloxacina è un 8-metossichinolone dotato di un ampio spettro d'azione antibatterico nei confronti dei batteri Grampositivi e Gram-negativi, aerobi ed anaerobi e dei patogeni atipici quali micoplasmi, legionelle e clamidie [3, 7, 8]. Questo nuovo antibiotico è tra i farmaci più potenti attualmente disponibili nei confronti dei batteri Gram-positivi, compresi lo Staphylococcus aureus meticillino-resistente e i pneumococchi, sia sensibili che resistenti alla penicillina. La moxifloxacina è attiva quanto la ciprofloxacina verso Legionella spp., ma più attiva verso Chlamydia spp. e Mycoplasma pneumoniae. Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomicoMario Eandi * Moxifloxacina manifesta minore efficacia rispetto a ciprofloxacina verso le Enterobatteriaceae e verso Pseudomonas aeruginosa. Dotata di una potente e rapida azione battericida concentrazione-dipendente verso i batteri Gram-positivi e di un marcato effetto post-antibiotico, la moxifloxacina si accumula rapidamente nei ceppi sensibili, agisce inibendo in ugual misura sia la DNA girasi sia la topoisomerasi IV e manifesta una ridotta tendenza a selezionare ceppi mutanti resistenti [1, 7].La farmacocinetica della moxifloxacina si caratterizza per la lunga emivita, circa 12 ore, per un'elevata biodisponibilità orale, un'eccellente diffusibilità tissutale extravascolare e per la scarsità di interazioni con altri farmaci [1, 7]. Il profilo di tollerabilità, simile a quello dei fluorochinoloni, si differenzia, tuttavia, per l'assenza di fototossicità [2]. ABSTRACTMoxifloxacin is a new fluorquinolone antibiotic, recently introduced among the treatment options for upper and lower airways infections. It possesses a wide antibiotic spectrum, covering the major pathogens involved in the genesis of community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis (ABS). It acts in a concentration-dependent manner by inhibition of bacterial DNAgirase and topoisomerase IV, has a long biological half-life (about 12 hours), good oral bioavailability, excellent tissue diffusion and a better safety profile than other quinolones, because of the lack of phototoxicity and the scarsity of clinically significant drug interactions. The clinical results of moxifloxacin in CAP, AECB and ABS have been compared with those of available alternative antibiotics in several multicentric, double-blind studies, and the new fluorquinolone resulted at least as effective as the comparators, with similar tolerability profiles. These studies demonstrated a high correlation among the eradication of the pathogen and the clinical recovery of the patients. The pharmacodynamics, pharmacokinetics and clinical results of moxifloxacin render it one of the most attractive options for the empirical treatment of upper and lower air...

show abstract

Effects of Subinhibitory Concentrations of Moxifloxacin in anIn-VitroDynamic Model

Cited by 6 publications

References 18 publications

Moxifloxacin‐based strategies for first‐line treatment of Helicobacter pylori infection

Moxifloxacin‐based strategies for first‐line treatment of Helicobacter pylori infection

Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication

Moxifloxacina: profilo farmacologico, terapeutico e farmacoeconomico

Contact Info

Product

Resources

About